PCMA on New PwC Report: PBMs Driving Competition to Reduce Drug Costs

Tuesday, June 21, 2016 Drug News J E 4

WASHINGTON, June 21, 2016  /PRNewswire-USNewswire/ -- The new PwC Health Research Institute (HRI) annual report  ("Medical Cost Trend: Behind the Numbers 2017") highlights how pharmacy benefit managers (PBMs) help reduce drug cost trend, specifically noting that: "With increased appetite from employers to narrow their formularies to one treatment option, PBMs are using competition between products to more aggressively negotiate drug costs. This is putting a downward pressure on the growth rate of total healthcare spending. Reflecting the demand for value, the future of PBM contracting points toward paying for results and cures, not fee-for-service, around drug costs."

Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the new report:

"This report underscores how PBMs are driving competition and in turn reducing costs for consumers, employers, government programs, and unions. Policymakers should embrace greater use of proven PBM tools and reject drugmaker and drugstore lobby mandates that would increase prescription drug costs."

PBMs are projected to save employers, unions, government programs, and consumers $654 billion — up to 30 percent — on drug benefit costs over the next decade.  Learn how PBMs reduce prescription drug costs and improve convenience and safety for consumers, employers, unions, and government programs at That's What PBMs Do.

PCMA is the national association representing America's pharmacy benefit managers (PBMs).  PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including:  commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, managed Medicaid plans, and others.


To view the original version on PR Newswire, visit:

SOURCE Pharmaceutical Care Management Association



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
iCAD Commends Final USPSTF Recommendations for Col...
Hematological Cancers Space Abounds with Innovatio...